Apogenix GmbH, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, announced today that it was able to expand the patent protection for its lead product candidate Apocepta .
http://www.drugs.com/news/apogenix-strengthens-patent-position-apocept-apg101-europe-canada-45686.html?
http://www.drugs.com/news/apogenix-strengthens-patent-position-apocept-apg101-europe-canada-45686.html?
No comments:
Post a Comment